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Introduction {#sec1}
============

At the end of 2019, patients with coronavirus disease 2019 (COVID-19) were identified in Wuhan, China ([@bib19]), infected by a novel coronavirus, now named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The World Health Organization (WHO) first declared this outbreak a public health emergency of international concern ([@bib13]) and subsequently a worldwide pandemic ([@bib4]) .

The genome sequence of SARS-CoV-2 bears 96% ([@bib24]) and 79.5% identity to that of a bat coronavirus and SARS-CoV, respectively ([@bib25]). Like SARS-CoV and MERS-CoV, SARS-CoV-2 belongs to the beta genus *Coronavirus* in the Corornaviridae family ([@bib9]). Clinically, several papers showed that most COVID-19 patients developed lymphopenia as well as pneumonia with higher plasma levels of pro-inflammatory cytokines in severe cases ([@bib2], [@bib6], [@bib22]), suggesting that the host immune system is involved in the pathogenesis ([@bib10], [@bib11]). Patients infected by SARS-CoV or MERS-CoV were previously reported to have antibody responses ([@bib7], [@bib14], [@bib18], [@bib21]) but exhibited defective expression of types I and II interferons (IFNs), indicative of poor protective immune responses ([@bib1], [@bib16], [@bib17]). However, to date, there were few studies in characterizing the immune responses ([@bib20], [@bib24]), especially adaptive immune responses to SARS-CoV-2 infection. Zhou et al. showed that COVID-19 patients exhibited nucleocapsid protein (NP)-specific antibody response, and in one patient, immunoglobulin M (IgM) peaked at day 9 after disease onset and then switched to IgG by week 2 ([@bib24]). They also reported that sera from several patients could inhibit SARS-CoV-2 entry in target cells, indicating involvement of humoral immunity. Krammer and colleagues detected anti-S antibodies in three COVID-19 patients as early as 3 days post symptom onset (<https://doi.org/10.1101/2020.03.17.20037713>). A case report recently published showed the kinetics of T cell subpopulations (T~FH~, CD4 and CD8) and SARS-CoV-2-specific antibody responses in one COVID-19 patient ([@bib15]). One COVID-19 patient in Finland was shown to possess a low level of neutralizing antibody titer ([@bib5]). However, virus-specific T lymphocytes and their relationships with neutralizing antibody titers in COVID-19 patients remains uncharacterized.

In this study, we collected blood from COVID-19 patients who have recently become virus-free and therefore were discharged and analyzed their SARS-CoV-2-specific antibody and T cell responses.

Results {#sec2}
=======

Detection of SARS-CoV-2-Specific Antibodies in COVID-19 Convalescent Subjects {#sec2.1}
-----------------------------------------------------------------------------

To understand immune responses to COVID-19, we assessed 14 patients who recently recovered from the infection. Their clinical and pathological characteristics were shown in [Table 1](#tbl1){ref-type="table"} . All the patients initially showed mild symptoms via computed tomography (CT) scan and were positive with SARS-CoV-2 nucleic acid testing. Of them, eight (patients 1--8) were newly discharged, whereas the remaining six were 2 weeks post discharge (follow-up patients, patients 9--14). Only three traveled to Wuhan city within the past 3 months. In line with the previous reports ([@bib18]), two patients (5 and 10) showed lymphopenia (normal range is 1.1→3.2 × 10e9 cells per L). Sera from three healthy donors ([@bib18]) were obtained before the SARS-CoV-2 outbreak (healthy donors 1--3). Three additional healthy donors (4--6) who had been in close contacts with the patients were recruited in this study. Human AB serum collected from healthy male AB donors in the United States (GemCell, CA) was used as a negative control.Table 1Clinical and Pathological Characteristics of the COVID-19 PatientsPt\#SexAgeTravel in WuhanFeverFatigueLymphocyteCountDays in hospitalBT CT ScanBT NA TestDischarge CT ScanDischarge NA Test1F51yesyesyes1.1 × 10^9^/L33patchy ground glass shadows on both lungsPimprovementN2F42nonono2.5 × 10^9^/L27multiple patchy ground glass and high-density shadows in both lungsPimprovementN3M32noyesno1.7 × 10^9^/L36exudative lesion of the right lower lungPimprovementN4M49noyesno1.5 × 10^9^/L32patchy ground glass shadows on both lungsPsignificant improvementN5F62noyesyes0.8 × 10^9^/L37patchy ground glass shadows on both lungsPsignificant improvementN6M32noyesyes2.1 × 10^9^/L17multiple ground glass shadows in both lungsPsignificant improvementN7M32noyesyes1.7 × 10^9^/L34multiple ground glass lesions in the lower lobe of the right lungPsignificant improvementN8F57yesyesyes1.3 × 10^9^/L45multiple flaky ground glass shadows in the subpleural areas of both lungs, some accompanied by consolidationPsignificant improvementN9F26noyesno2.9 × 10^9^/L12right lung inflammationPnormalN10M68noyesno0.7 × 10^9^/L14multiple patchy ground glass shadows are seen in the left lung, and the upper lobe of the left lung is obviousPsignificant improvementN11F37nonoyes1.9 × 10^9^/L12double lung veins thickenedPnormalN12F29noyesyes1.9 × 10^9^/L13ground glass in the pleura of the lower lobe of both lungsPnormalN13F31yesyesno1.1 × 10^9^/L19patchy ground glass shadows on both lungsPsignificant improvementN14M35noyesyes2.3 × 10^9^/L11multiple ground glass shadows in both lungsPnormalN[^3]

In order to detect anti-viral immune responses, we first constructed recombinant pET28-N-6XHis by linking six copies of His tag to the C terminus of NP in the pET28-N vector (Biomed, cat. number BM2640). *Escherichia coli* transformed with pET28-N-6xHis was lysed and tested by Coomassie blue staining to confirm NP expression at 45.51 kDa. NP was further purified by Ni-NTA affinity chromatography and gel filtration. The purity of NP was approximately 90% ([Figure S1](#mmc1){ref-type="supplementary-material"}A). The presence of NP was subsequently confirmed by anti-FLAG antibody ([Figure S1](#mmc1){ref-type="supplementary-material"}B). The receptor-binding domain (RBD) of S protein (S-RBD) and main protease ([@bib8]) were produced by a Baculovirus insect expression system and purified to a purity of 90% ([Figure S1](#mmc1){ref-type="supplementary-material"}A).

Using sera from patients and healthy donors, IgG and IgM against SARS-CoV-2 NP, main protease and S-RBD antigens were analyzed. There was no significant antibody response to main protease in sera from several patients (data not shown), suggesting that it may not serve as an antigen for humoral immunity. We thus focused on NP and S-RBD. The individual serum samples were then performed by serial dilutions to get optimal dilutions ([Figure 1](#fig1){ref-type="fig"} A). Dilution of 1:50 was used for IgM and 1:450 for IgG. NP- and S-RBD-specific IgM and IgG antibodies were both detected in the sera of newly discharged patients, compared with healthy donor groups. Anti-SARS-CoV-2 IgG antibodies were also more obviously observed than IgM in the follow-up patients (9--14) when compared with healthy donors ([Figure 1](#fig1){ref-type="fig"}B). In addition, values from the serum dilution curves were calculated to determine the area under the curve (AUC) values. Compared to control sera, COVID-19 patient sera showed significantly higher AUC for NP- and S-RBD-specific IgG antibodies ([Figure 1](#fig1){ref-type="fig"}C). Taken together, these findings indicate that COVID-19 patients mounted IgG and IgM responses to SARS-CoV-2 proteins, especially NP and S-RBD, and also suggest that infected patients could maintain their IgG amounts, at least for 2 weeks after discharge.Figure 1SARS-CoV-2 NP- and S-RBD-Specific Antibodies in COVID-19 Convalescent Individuals(A) Titration of individual serum samples.(B) Serological responses of 14 COVID-19 patients to recombinant NP (top) and S-RBD (bottom). Dilution of 1:50 was used for IgM and 1:450 for IgG.(C) Data from the same experiments with (A) were presented as AUC.(D) IgG isotypes of 14 COVID-19 patients to recombinant NP and S-RBD.NP, nucleocapsid protein; S-RBD, receptor binding domain of spike protein; HD, healthy donor; Pt, patient; AUC, area under curve. The experiment was performed in duplicates. Date are presented as mean ± SEM. For HD 1--3, the sera were collected in 2018. For HD 4--6, the sera were from close contacts and collected in 2020. ^∗^p \< 0.05, 0.05 \< ^∗∗^p \< 0.001, ^∗∗∗^p \< 0.001.

In addition, IgG isotypes was further tested in 14 patients and 6 controls. As shown in [Figure 1](#fig1){ref-type="fig"}D, anti-NP and S-RBD IgG was mainly IgG1 isotype, and the newly discharged and follow-up patients showed similarly amounts of anti-NP IgG1. Of interest, one patient (5) showed higher amounts of anti-NP IgG3, whereas anti-S-RBD IgG3 was detected in two patients (4 and 5). However, we did not detect IgG2 to either NP or S-RBD proteins (data not shown).

Measurement of Neutralizing Antibody Titers from COVID-19 Convalescent Subjects {#sec2.2}
-------------------------------------------------------------------------------

Since the RBD of the S protein has been shown to bind to human angiotensin converting enzyme 2 (ACE2) ([@bib24]), the existence of antibodies against it may suggest neutralization of SARS-CoV-2 infection. To assess this, we performed a pseudovirus particle-based neutralization assay, since there was a significantly positive correlation in the neutralizing antibody titers between pseudovirus and SARS-CoV-2 ([Figure 2](#fig2){ref-type="fig"} A). As shown in [Figures 2](#fig2){ref-type="fig"}B and 2C, patients 1, 2, 4, 5, and 8, all within the newly discharged group, had high neutralizing antibody titers. These results demonstrate that most recently discharged patients had strong humoral immunity to SARS-CoV-2. Among the follow-up patients, all had neutralizing antibody titers, with the exception of patient 9 being negative. As expected, there was a significant correlation between neutralizing antibody titers and AUC of anti-S-RBD IgG, but not of anti-NP IgG ([Figure 2](#fig2){ref-type="fig"}D), suggesting that anti-S-RBD IgG might be predictive of serum neutralization capabilities in COVID-19 patients. These findings suggest that most patients post discharge have serum neutralizing SARS-CoV-2 infection.Figure 2Measurement of Neutralizing Antibody Titers in COVID-19 Convalescent Individuals(A) Correlation analysis of neutralizing antibody titers in COV1D-19 patients measured by pseudovirus and live SARS-CoV-2 (n = 20).(B) Neutralizing curves of 14 COVID-19 patients measured by pseudovirus-based assay. The experiment with patients was performed in triplicates. The experiment with healthy donors was performed in duplicates.(C) Measurement of neutralizing antibody titers of 14 COVID-19 patients by pseudovirus-based assay.(D) Correlation between NAT50 and AUC of anti-S-RBD (left) and anti-NP (right) IgG (n = 14).HD, healthy donor; Pt, patient; AUC, area under curve; NAT50, neutralizing antibody titers. Date are presented as mean ± SEM. ^∗^p \< 0.05, 0.05 \< ^∗∗^p \< 0.001, ^∗∗∗^p \< 0.001.

Cellular Immune Responses to SARS-CoV-2 in COVID-19 Convalescent Subjects {#sec2.3}
-------------------------------------------------------------------------

To explore cellular immune responses to SARS-CoV-2, we isolated peripheral blood monocytic cells (PBMCs) from the whole blood and phenotypically analyzed them by flow cytometry ([Figure 3](#fig3){ref-type="fig"} A). We found that compared to newly discharged patients, there was a trend toward an increased frequency of NK cells in the follow-up patients ([Figure 3](#fig3){ref-type="fig"}B). However, there was no significant difference in terms of the percentages of T cells among those two groups and the healthy donors.Figure 3T cell Responses to Recombinant SARS-CoV-2 Proteins in COVID-19 Convalescent Individuals(A) Phenotypic analysis of PBMCs from representative COVID-19 patients.(B) Summarized data on the frequencies of different immune cell subsets in COVID-19 patients. HD, healthy donors (n = 2); D-Pt, discharged patients (n = 3); F-Pt, follow-up patients (n = 5).(C) IFN-γ ELISpot analysis of COVID-19 patients to recombinant proteins. The experiments were performed in duplicates.(D) Correlation analysis of the NAT50 and the numbers of NP-specific T cells (n = 14).M protease, main protease; NP, nucleocapsid protein; S-RBD, receptor binding domain of spike protein; NAT50, neutralizing antibody titers. Date are presented as mean ± SEM.

To assess virus-specific cellular immunity, we then treated PBMCs with recombinant NP, main protease, and S-RBD, followed by IFN-γ ELISpot analysis. The results were considered positive if there was at least a 2-fold increase in the numbers of IFN-γ-secreting T cells in the subject than in the healthy donors. As shown in [Figure 3](#fig3){ref-type="fig"}C, compared with healthy donors, the numbers of IFN-γ-secreting NP-specific T cells in patients 1, 2, 4, 5, and 8 were much higher than other patients, suggesting that they had developed SARS-CoV-2-specific T cell responses. Of note, patients 1, 2, 4, 5, and 8 developed both strong humoral and cellular immune responses. Main protease-specific T cells were detected in patients 1, 2, and 5, while patients 1, 2, 4, 5, 6, 7, and 8 showed S-RBD-specific T cells. Although the numbers of IFN-γ-secreting S-RBD specific T cells were much lower than those of NP-specific T cells, they could be detected in more patients than those for other viral proteins. In the follow-up patients, only patient 10, who showed lymphopenia before treatment, still had a high number of IFN-γ-secreting T cells in response to NP, main protease, and S-RBD ([Figure 3](#fig3){ref-type="fig"}C), which suggests that anti-viral T cells may not be maintained at high numbers in the PBMCs in the recovered patients. More interestingly, when combining all 14 patients in our analysis, there was a significant correlation between the neutralizing antibody titers and the numbers of NP-specific T cells ([Figure 3](#fig3){ref-type="fig"}D), indicating that the development of neutralizing antibodies may be correlated with the activation of anti-viral T cells. Thus, effective clearance of virus may need collaborative humoral and cellular immune responses.

Discussion {#sec3}
==========

In this study, we characterized SARS-CoV-2-specific humoral and cellular immunity in recovered patients. Both were detected in newly discharged patients. In addition, the neutralizing antibody titers significantly correlated with the numbers of NP-specific T cells. These findings suggest both B and T cells participate in immune-mediated protection to viral infection. Our work has thus provided a basis for further analysis of protective immunity to SARS-CoV-2 and understanding the pathogenesis of COVID-19, especially in the severe cases. It has also implications in designing an effective vaccine to protect and treat SARS-CoV-2 infection.

In our study, production of S-RBD-specific antibodies were readily detected in recovered patients. Moreover, we observed virus-neutralization activities in these recovered patients. Not surprisingly, a significant correlation between neutralizing antibody titers and AUC of anti-S-RBD IgG, but not anti-NP IgG, was observed. Anti-S-RBD IgG might be useful in analyzing serum neutralization capabilities in COVID-19 patients. Our data are consistent with the work from other investigators ([@bib24]), in keeping with the role of humoral immunity in blockade of receptor binding during viral entry in host cells. Interestingly, S-RBD-specific T cell production of IFN-γ was also noted, suggesting that S-RBD also induced broader T cell immune responses. S-RBD, thus, is a promising target for SARS-CoV-2 vaccines.

Similar to a recent preprint (<https://doi.org/10.1101/2020.03.30.20047365>) published online after ours, the titers of neutralizing antibodies were variable in recovered patients, ranging from below detection (\<30) to 1,936. Patient 9 did not exhibit significant serum virus-neutralizing activities. This patient, though with anti-NP and S-RBD IgM, did not have significant IgG or IgG1 production. Interestingly, this patient had detectable virus-specific T cell function. The basis for the neutralization deficiency in this patient and whether the patient can generate neutralizing antibodies thereafter needs further investigation. Nonetheless, in our study and the one mentioned above, most patients developed measurable neutralization antibodies after infection, suggesting that the viral infection does not curtail adaptive immunity. However, unlike the above-mentioned study, we did not find any correlation between neutralizing antibody titers and patients' age, which could be due to our small sample size. Our results thus need further confirmation in a large cohort of COVID-19 patients. In addition, our analysis could not differentiate CD4^+^ and CD8^+^ T cell responses, due to the limitation in the amounts of PBMCs obtained and availability of instrumentation.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Anti-CD45 (clone H130)BioLegendCat\# 304028; RRID:[AB_893338](nif-antibody:AB_893338){#interref40}Anti-CD3 (clone OKT3)BioLegendCat\# 317334; RRID:[AB_2561452](nif-antibody:AB_2561452){#interref45}Anti-CD8 (clone SK1)BD BiosciencesCat\# 557834; RRID:[AB_396892](nif-antibody:AB_396892){#interref50}Anti-CD56 (clone HCD56)BioLegendCat\# 318304; RRID:[AB_604100](nif-antibody:AB_604100){#interref55}Anti-CD38 (clone HIT2)BioLegendCat\# 303508**Chemicals, Peptides, and Recombinant Proteins**Fixable viability dye eFluor660eBioscienceCat\# 65-0864FcR blocking reagentMeltenyi Biotec,Cat\# 130-059-901Ficoll-Hypaque gradientGE Healthcare LifeCat\# 17144002Goat anti-human IgM/HRPBiosynthesisCat\# bs-0345G-HRP; RRID:[AB_10892735](nif-antibody:AB_10892735){#interref60}Goat anti-human IgG(biotin)Sino BiologicalCat\# SSA009HRP Mcab mouse anti-human IgG1BaiaoTongCat\# C030248HRP Mcab mouse anti-human IgG2BaiaoTongCat\# C030245HRP Mcab mouse anti-human IgG3BaiaoTongCat\# C030246TMB substrateInvitrogenCat\# 00-4201-56Mouse anti-His monoclonal antibodyProteintechCat\# HRP-66005Recombinant His-tagged NP of SARS-CoV-2In-houseN/ARecombinant His-tagged S-RBD of SARS-CoV-2[@bib8]N/ARecombinant main protease of SARS-CoV-2[@bib8]N/A**Critical Commercial Assays**Fixation/Permeabilization Solution KitBD BiosciencesCat\# 554714Human IFN-γELISpot^pro^ kitMABTECHCat\# 3420-2AST-2**Biological Samples**Human AB serumGemCellCat\# 100-512Sera from HD\#1-3In-houseN/ABlood samples from HD\#4-6ChuiYangLiu HospitalN/ABlood samples from COVID-19 patientsChuiYangLiu HospitalN/A**Experimental Models: Organisms/Strains**HuH-7 Cells[@bib12]N/A**Software and Algorithms**FlowJo software v10.7FlowJo LLC<https://www.flowjo.com/>; RRID:[SCR_008520](rridsoftware:SCR_008520){#intref0025}

Resource Availability {#sec4.2}
---------------------

### Lead Contact {#sec4.2.1}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Chen Dong (<chendong@tsinghua.edu.cn>)

### Materials Availability {#sec4.2.2}

The plasmid (pET28-N-6XHis) generated in this study will be made available on request from the Lead Contact without restriction.

### Data and Code Availability {#sec4.2.3}

The study did not generate any unique dataset or code.

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### COVID-19 patient blood samples {#sec4.3.1}

The blood samples of COVID-19 patients and healthy donors were obtained from Chui Yang Liu Hospital affiliated to Tsinghua University in Beijing. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (the institutional review board at Tsinghua University) and with the Helsinki Declaration of 1975, as revised in 2000. All studies were approved by the Medical Ethical Committee at Tsinghua University. Informed consent was obtained from all subjects for being included in the study. All patient data were anonymized before study inclusion. See [Table 1](#tbl1){ref-type="table"} for full patient information, including age, sex, and health status.

### Cell Lines {#sec4.3.2}

HuH-7 cells originally taken from a liver tumor in a Japanese male were cultured in DMEM supplemented with 10% FBS. Cells were grown at 37°C in a 5% CO2 setting.

Method Details {#sec4.4}
--------------

### Expression and Purification of recombinant proteins {#sec4.4.1}

The recombinant His-tagged NP of SARS-CoV-2 was expressed in *E. coli* by a T7 expression system, with 1 mM IPTG induction at 37°C for 4 h. The recombinant His-tagged S-RBD (amino acids 319-541) was expressed by a Baculovirus system in insect cells ([@bib8]). Purified proteins were identified by SDS-PAGE gels and stained with Coomassie blue. Western blot was performed to confirm their antigenicity by mouse anti-His monoclonal antibody (Proteintech, HRP-66005).

### Isolation of PBMC {#sec4.4.2}

PBMCs were isolated from anti-coagulant blood using Ficoll-Hypaque gradients (GE Healthcare Life Sciences, Philadelphia, PA) as previously described ([@bib23]) under the biosafety level 3 facility in AMMS. To isolate PBMCs, blood diluted with PBS, was gently layered over an equal volume of Ficoll in a Falcon tube and centrifuged for 30-40 min at 400-500 g without brake. Four layers formed, each containing different cell types. The second layer contained PBMCs. These cells could be gently removed using a Pasteur pipette and added to warm medium or PBS to wash off any remaining platelets. The pelleted cells were then counted and the percentage viability was estimated using Trypan blue staining. Cells were used immediately.

### Anti-SARS-CoV-2 IgG/IgM ELISA {#sec4.4.3}

For IgM/IgG testing, 96-well ELISA plates were coated overnight with recombinant NP and S-RBD (100 ng/well). The sera from COVID-19 patients were incubated for 1 h at 37°C. An anti-Human IgG-biotin conjugated monoclonal antibody (Cat. SSA009, Sino Biological Inc., Wayne, PA) and streptavidin-HRP were used at a dilution of 1: 5000 and 1:250, respectively, and anti-human IgM-HRP conjugated monoclonal antibody (Cat. bs-0345G-HRP, Biosynthesis Biotechnology Inc. Beijing, China) was used. The OD value at 450 nm was calculated. The area under the curve (AUC) was calculated by Prism 7 (Graphpad).

### Anti-SARS-CoV-2 IgG1/IgG2/IgG3 ELISA {#sec4.4.4}

For IgG1/IgG2/IgG3 test, 96 well ELISA plates were coated (80 ng/well) overnight with recombinant NP and S-RBD. Plates were washed and the sera from COVID-19 patients were incubated for 1 h at 37°C. After washing, an anti-Human IgG1-HRP conjugated monoclonal antibody (Cat. C030248, BaiaoTong Experiment Center, LY), an anti-human IgG2-HRP conjugated monoclonal antibody (Cat. C030245, BaiaoTong Experiment Center, LY) and an anti-human IgG3-HRP conjugated monoclonal antibody (Cat.C030246, BaiaoTong Experiment Center, LY), all validated by the company for their specificity, were used at a dilution of 1:4000 for 1 h at RT. After washing, TMB substrate solution was added. The OD value at 450 nm was calculated.

### Neutralizing antibody assay {#sec4.4.5}

Pseudovirus expressing the SARS-CoV-2 S protein was produced as described previously ([@bib3]). pNL43Luci and GP-pCAGGS were co-transfected into 293T cells. 48 h later, SARS-CoV-2 pseudovirus-containing supernatants were mixed with at least 6 serially diluted serum samples from the COVID-19 patients at 37°C for 1 h. Then the mixtures were transferred to 96-well plates containing monolayers of Huh-7 cells ([@bib12]). 3 h later, the medium was replaced. After incubation for 48 h, the cells were washed, harvested in lysis buffer and analyzed for luciferase activity by the addition of luciferase substrate. Inhibition rate = \[1-(the sample group- the cell control group) / (the virus control group- the cell control group)\] x 100%. The neutralizing antibody titer (NAT50) were calculated by performing S-fit analysis via Graphpad Prism 7 software.

### Interferon Gamma (IFN-γ) ELISpot {#sec4.4.6}

IFN-γ-secreting T cells were detected by Human IFN-γ ELISpot^pro^ kits (MABTECH AB, Sweden) according to the manufacture protocol. Fresh PBMCs were plated in duplicate at 150k per well and then incubated 48 h with 1uM of recombinant proteins. Spots were then counted using an ELIspot Reader System (AT-Spot2100, atyx). The number of spots was converted into the number of spots per million cells and the mean of duplicate wells plotted.

### FACS staining {#sec4.4.7}

PBMCs were washed with PBS plus 2% FBS (GIBCO, Grand Island, NY), and then Fc blocking reagent (Meltenyi Biotec, Inc., Auburn, CA) was added followed by a wash with PBS plus 2% FBS. Cells were then incubated for 30 min on ice with anti-CD45 (H130) (BioLegend), anti-CD3 (OKT3) (BioLegend), anti-CD8 (SK1) (BD), anti-CD56 (HCD56) (BioLegend), anti-CD38 (HIT2) (BioLegend) and live/dead fixable aqua dye (eF660, eBioscience), washed twice with PBS plus 2% FBS and then stored at 4°C until acquired by FACS Verse (BD Biosciences, San Jose, CA). Data were analyzed using FlowJo software (Version 10.0.8, Tree Star Inc., Ashland, Or).

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Prism 7 software is used for statistical analysis. Student's t test was performed for two-group analysis. Pearson's correlation coefficients were calculated. *P* values less than 0.05 were considered to be statistically significant.

Supplemental Information {#app2}
========================

Figure S1. Expression and Purification of NP and S-RBD Proteins, Related to Figures 1, 2, and 3 Document S1. Article plus Supplemental Information
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